A Phase 1/2 interventional study of Placebo and Docetaxel in Breast Neoplasms, sponsored by Pfizer. Completed at 54 sites in 8 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-06-26.
Sponsored by Pfizer · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 182 studies in Breast Neoplasms by Pfizer — 6 open to participants now, 26 under way, 7 of them phase 3. Breast Neoplasms · Pfizer.
Among the 182 studies in Breast Neoplasms by Pfizer, this one is the 39th largest by enrollment of the 121 interventional ones that give a count, is one of 5 that started in 2004, is one of 13 in phase 1/2, and was the 13th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →6 of the 182 studies in Breast Neoplasms by Pfizer are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States, France, Spain
Ages 18+
Pfizer · Sites in United States, Argentina, Australia and 28 more countries
Ages 18+
Pfizer · Sites in United States, Argentina, China and 5 more countries
Ages 18+
Pfizer
Ages 18+
Pfizer
Ages 18+
By country, each count listing its studies:
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
182 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 50 · Phase 2 56 · Phase 3 25 · Phase 4 3
First in 1998; this study’s year is marked. 5 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 174 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 75 across the 121 interventional studies, 399 across the 56 observational. Of the 145 that completed or were terminated, 94 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
8 of the studies in Breast Neoplasms by Pfizer that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05909397Phase 3PfizerVepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer | 2026-12-30 |
| NCT07062965Phase 3PfizerA Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. | 2027-07-22 |
| NCT06495164PfizerA Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer | 2026-12-30 |
| NCT04553133PfizerPF-07104091 as a Single Agent and in Combination Therapy | 2026-12-31 |
| NCT05382364PfizerSafety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002) | 2026-12-31 |
Add all 8 to your calendar (.ics) → With an account.
Among the 182 studies in Breast Neoplasms by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary purpose of the study is to determine the time to progression of the combination of study drug (AG-013736) and docetaxel versus docetaxel alone in patients who have not received prior chemotherapy for metastatic breast cancer. The secondary purpose of the study is to determine the dose of study drug that can be given with docetaxel administered on an every 3 week schedule.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Docetaxel + Placebo
Drug: Placebo · Drug: Docetaxel
Docetaxel + AG-013736
Drug: AG-013736 (axitinib) · Drug: Docetaxel
Time to Tumor Progression (TTP)
Time in days from start of study treatment to first documentation of objective tumor progression or death due to cancer, whichever comes first. TTP was calculated as first event date minus the date of first dose of study medication plus 1. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]).
Time frame: Phase 2 double-blind baseline until tumor progression or death or discontinuation from study treatment, assessed every 9 weeks up to 129 weeks
Percentage of Participants With Objective Response (OR) for Phase 2 (Double-blind)
Percentage of participants with OR based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. CR are defined as the disappearance of all lesions (target and/or non target). PR are those with at least 30 percent (%) decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.
Time frame: Phase 2 double- blind baseline until the date of first documented progression or discontinuation from the study treatment due to any cause, assessed every 9 weeks up to 129 weeks
Percentage of Participants With Objective Response (OR) for Phase 2 (Open-label)
Percentage of participants with OR based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. CR are defined as the disappearance of all lesions (target and/or non target). PR are those with at least 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.
Time frame: Phase 2 open-label baseline until the date of first documented progression or discontinuation from the study due to any cause, assessed every 8 weeks up to 58 weeks
Duration of Response (DR) for Phase 2 (Double-blind)
Time in days from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1. DR was calculated for the subgroup of participants with a confirmed objective tumor response.
Time frame: Phase 2 double-blind baseline until the date of first documented progression or discontinuation from the study due to any cause, assessed every 9 weeks up to 129 weeks
Duration of Response (DR) for Phase 2 (Open-label)
Time in days from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1. DR was calculated for the subgroup of participants with a confirmed objective tumor response.
Time frame: Phase 2 open-label baseline until the date of first documented progression or discontinuation from the study due to any cause, assessed every 8 weeks up to 58 weeks
Population Pharmacokinetics of Axitinib (AG-013736) for Phase 2 (Double-blind)
Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.
Time frame: Day 1 (pre-dose), Day 22 and Day 43 and then every 9 weeks up to 129 weeks
| Milestone | Axitinib + Docetaxel (Phase-1, Lead-in) | Axitinib + Docetaxel (Phase 2, Double-blind) | Docetaxel + Placebo (Phase 2, Double-blind) | Axitinib (Phase 2, Open-label) |
|---|---|---|---|---|
| Started | 6 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 6 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 4 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 |
| Withdrew: Clinical progression | 1 | 0 | 0 | 0 |
| Milestone | Axitinib + Docetaxel (Phase-1, Lead-in) | Axitinib + Docetaxel (Phase 2, Double-blind) | Docetaxel + Placebo (Phase 2, Double-blind) | Axitinib (Phase 2, Open-label) |
|---|---|---|---|---|
| Started | 0 | 112 | 56 | 0 |
| Treated | 0 | 111 | 56 | 0 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 0 | 112 | 56 | 0 |
| Withdrew: Lack of efficacy | 0 | 59 | 40 | 0 |
| Withdrew: Withdrawal by subject | 0 | 13 | 4 | 0 |
| Withdrew: Adverse event | 0 | 25 | 6 | 0 |
| Withdrew: Un-specified | 0 | 14 | 6 | 0 |
| Withdrew: Randomized but not treated | 0 | 1 | 0 | 0 |
| Milestone | Axitinib + Docetaxel (Phase-1, Lead-in) | Axitinib + Docetaxel (Phase 2, Double-blind) | Docetaxel + Placebo (Phase 2, Double-blind) | Axitinib (Phase 2, Open-label) |
|---|---|---|---|---|
| Started | 0 | 0 | 0 | 16 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 16 |
| Withdrew: Adverse event | 0 | 0 | 0 | 2 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 11 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 |
| Withdrew: Other | 0 | 0 | 0 | 2 |
Time in days from start of study treatment to first documentation of objective tumor progression or death due to cancer, whichever comes first. TTP was calculated as first event date minus the date of first dose of study medication plus 1. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]).
| days | Axitinib + Docetaxel (Phase 2, Double-blind) | Docetaxel + Placebo (Phase 2, Double-blind) |
|---|---|---|
| Time to Tumor Progression (TTP) | 247 (208 to 265) | 215 (191 to 247) |
Percentage of participants with OR based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. CR are defined as the disappearance of all lesions (target and/or non target). PR are those with at least 30 percent (%) decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.
| percentage of participants | Axitinib + Docetaxel (Phase 2, Double-blind) | Docetaxel + Placebo (Phase 2, Double-blind) |
|---|---|---|
| Percentage of Participants With Objective Response (OR) for Phase 2 (Double-blind) | 41.1 (31.9 to 50.8) | 23.6 (13.2 to 37.0) |
Percentage of participants with OR based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. CR are defined as the disappearance of all lesions (target and/or non target). PR are those with at least 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.
| percentage of participants | Axitinib (Phase 2, Open-label) |
|---|---|
| Percentage of Participants With Objective Response (OR) for Phase 2 (Open-label) | 6.3 (0.2 to 30.2) |
Time in days from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1. DR was calculated for the subgroup of participants with a confirmed objective tumor response.
| days | Axitinib + Docetaxel (Phase 2, Double-blind) | Docetaxel + Placebo (Phase 2, Double-blind) |
|---|---|---|
| Duration of Response (DR) for Phase 2 (Double-blind) | 211 (190 to 276) | 149 (120 to 238) |
Time in days from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1. DR was calculated for the subgroup of participants with a confirmed objective tumor response.
| days | Axitinib (Phase 2, Open-label) |
|---|---|
| Duration of Response (DR) for Phase 2 (Open-label) | 1.0 (NA to NA) |
Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.
Results for this outcome have not been posted.
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Axitinib + Docetaxel (Phase-1 Lead-in) | — | 1/6 (16.7%) | 6/6 (100%) |
| Axitinib + Docetaxel (Phase 2, Double-blind) | — | 54/111 (48.6%) | 111/111 (100%) |
| Docetaxel + Placebo (Phase 2, Double-blind) | — | 17/56 (30.4%) | 56/56 (100%) |
| Axitinib (Phase 2, Open-label) | — | 2/16 (12.5%) | 12/16 (75%) |
| Event | Axitinib + Docetaxel (Phase-1 Lead-in) | Axitinib + Docetaxel (Phase 2, Double-blind) | Docetaxel + Placebo (Phase 2, Double-blind) | Axitinib (Phase 2, Open-label) |
|---|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 1/6 | 9/111 | 3/56 | 0/16 |
| StomatitisGastrointestinal disorders | 1/6 | 5/111 | 0/56 | 0/16 |
| NeutropeniaBlood and lymphatic system disorders | 0/6 | 10/111 | 3/56 | 0/16 |
| HypothyroidismEndocrine disorders | 0/6 | 0/111 | 0/56 | 1/16 |
| ConvulsionNervous system disorders | 0/6 | 0/111 | 0/56 | 1/16 |
| PyrexiaGeneral disorders | 0/6 | 6/111 | 1/56 | 0/16 |
| DiarrhoeaGastrointestinal disorders | 0/6 | 4/111 | 1/56 | 0/16 |
| NauseaGastrointestinal disorders | 0/6 | 4/111 | 2/56 | 0/16 |
| VomitingGastrointestinal disorders | 0/6 | 4/111 | 2/56 | 0/16 |
| DehydrationMetabolism and nutrition disorders | 0/6 | 4/111 | 1/56 | 0/16 |
| Event | Axitinib + Docetaxel (Phase-1 Lead-in) | Axitinib + Docetaxel (Phase 2, Double-blind) | Docetaxel + Placebo (Phase 2, Double-blind) | Axitinib (Phase 2, Open-label) |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 5/6 | 69/111 | 24/56 | 4/16 |
| NauseaGastrointestinal disorders | 5/6 | 54/111 | 19/56 | 10/16 |
| Nail disorderSkin and subcutaneous tissue disorders | 5/6 | 23/111 | 14/56 | 0/16 |
| NeutropeniaBlood and lymphatic system disorders | 4/6 | 39/111 | 20/56 | 0/16 |
| Abdominal painGastrointestinal disorders | 4/6 | 26/111 | 5/56 | 2/16 |
| Oral painGastrointestinal disorders | 4/6 | 11/111 | 5/56 | 3/16 |
| VomitingGastrointestinal disorders | 4/6 | 42/111 | 17/56 | 5/16 |
| FatigueGeneral disorders | 4/6 | 52/111 | 24/56 | 7/16 |
| DehydrationMetabolism and nutrition disorders | 4/6 | 12/111 | 0/56 | 1/16 |
| DysgeusiaNervous system disorders | 4/6 | 25/111 | 10/56 | 1/16 |
| Age Continuous(Years) | Axitinib + Docetaxel (Phase 1, Lead-in) | Axitinib + Docetaxel (Phase 2, Double-blind) | Docetaxel + Placebo (Double-blind) | Total |
|---|---|---|---|---|
| Mean | 50.80 ± 9.68 | 54.10 ± 10.43 | 54.70 ± 10.12 | 54.2 ± 10.3 |
| Sex: Female, Male(Participants) | Axitinib + Docetaxel (Phase 1, Lead-in) | Axitinib + Docetaxel (Phase 2, Double-blind) | Docetaxel + Placebo (Double-blind) | Total |
|---|---|---|---|---|
| Female | 6 | 112 | 56 | 174 |
| Male | 0 | 0 | 0 | 0 |
The record gives a start of Feb 2004, a primary completion of Jan 2007 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2012, 5 years 2 months after primary completion. A results delay was requested in Mar 2009.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Axitinib